408 related articles for article (PubMed ID: 27546844)
1. Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.
Martínez-Marín V; Maki RG
Gastroenterol Clin North Am; 2016 Sep; 45(3):477-86. PubMed ID: 27546844
[TBL] [Abstract][Full Text] [Related]
2. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
3. Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS.
Fredebohm J; Mehnert DH; Löber AK; Holtrup F; van Rahden V; Angenendt P; Diehl F
Adv Exp Med Biol; 2016; 924():187-189. PubMed ID: 27753042
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
5. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
6. GEIS guidelines for gastrointestinal sarcomas (GIST).
Poveda A; García Del Muro X; López-Guerrero JA; Cubedo R; Martínez V; Romero I; Serrano C; Valverde C; Martín-Broto J;
Cancer Treat Rev; 2017 Apr; 55():107-119. PubMed ID: 28351781
[TBL] [Abstract][Full Text] [Related]
7. Perioperative treatment of gastrointestinal stromal tumors.
Fernandes Gdos S; Blanke CD; Freitas D; Guedes R; Hoff PM
Oncology (Williston Park); 2009 Jan; 23(1):54-61. PubMed ID: 19283922
[TBL] [Abstract][Full Text] [Related]
8. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
[TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
10. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
Xu J; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
[TBL] [Abstract][Full Text] [Related]
11. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
12. Treatment of gastrointestinal stromal tumours in paediatric and young adult patients with sunitinib: a multicentre case series.
Rutkowski P; Magnan H; Chou AJ; Benson C
BMC Cancer; 2017 Nov; 17(1):717. PubMed ID: 29110655
[TBL] [Abstract][Full Text] [Related]
13. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
[No Abstract] [Full Text] [Related]
14. [Treatment of Regorafenib in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib].
Saito Y; Takahashi T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
Gan To Kagaku Ryoho; 2018 Jan; 45(1):121-123. PubMed ID: 29362328
[TBL] [Abstract][Full Text] [Related]
15. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
Hong JL; Li J; Li J; Shen L
Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
Heinrich MC; Rankin C; Blanke CD; Demetri GD; Borden EC; Ryan CW; von Mehren M; Blackstein ME; Priebat DA; Tap WD; Maki RG; Corless CL; Fletcher JA; Owzar K; Crowley JJ; Benjamin RS; Baker LH
JAMA Oncol; 2017 Jul; 3(7):944-952. PubMed ID: 28196207
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ; Zalupski MM
J Surg Oncol; 2011 Dec; 104(8):901-6. PubMed ID: 22069175
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
[TBL] [Abstract][Full Text] [Related]
19. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Reichardt P; Reichardt A
Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of regorafenib in colorectal cancer and GIST.
Waddell T; Cunningham D
Lancet; 2013 Jan; 381(9863):273-5. PubMed ID: 23177516
[No Abstract] [Full Text] [Related]
[Next] [New Search]